Novonix (NVNXF) Common Equity (2020 - 2025)

Novonix has reported Common Equity for 6 years, with the latest figure at $161.7 million in Q4 2025.

• For the quarter ending Q4 2025, Common Equity rose 17.5% year-over-year to $161.7 million; the trailing twelve-month figure through Dec 2025 stood at $161.7 million (up 17.5% YoY), and the FY2025 full-year result was $161.7 million, up 17.5% from the prior year.
• Common Equity for Q4 2025 stood at $161.7 million, up from $144.1 million in the prior quarter.
• The five-year high for Common Equity was $272.5 million in Q4 2021, with the low at $137.6 million in Q4 2024.
• Historically, Common Equity has averaged $188.9 million across 5 years, with a median of $172.8 million in 2023.
• Annual changes were most pronounced in 2021 — Common Equity surged 218.89% — and 2024, when it decreased 25.2%.
• Novonix's Common Equity stood at $272.5 million in 2021, then slipped by 17.04% to $226.1 million in 2022, then fell by 18.63% to $183.9 million in 2023, then declined by 25.2% to $137.6 million in 2024, then advanced by 17.5% to $161.7 million in 2025.
• The last three Common Equity figures came in at $161.7 million (Q4 2025), $144.1 million (Q2 2025), and $137.6 million (Q4 2024), per Business Quant data.